University of Texas Southwestern Medical Center 9th Annual Update on Liver Disease 2025

1. Overview
The University of Texas Southwestern Medical Center 9th Annual Update on Liver Disease 2025 provides an advanced clinical review of modern hepatology. The program explores the latest evidence-based strategies for diagnosing and managing complex liver conditions, including MASH, alcohol-associated liver disease (ALD), autoimmune hepatitis, complications of cirrhosis, and hepatocellular carcinoma.
Course Date: Dec. 6, 2025
The Ninth Annual Liver Conference, a one-day, hybrid course for gastroenterologists, GI surgeons, internists, family practice physicians, nurse practitioners, physician assistants, and other healthcare providers with an interest in gastroenterology and hepatology is scheduled for Saturday, Dec. 6, 2025, from 8 a.m. to 5 p.m. in the Conference Center at Pegasus Park. Under the direction of Indira Bhavsar-Burke, M.D., M.H.P.E., an Assistant Professor in the Division of Digestive and Liver Diseases and Associate Director of the Gastroenterology Fellowship, and Amit Singal, M.D., M.S., Professor and Interim Division Chief of Digestive and Liver Diseases, the course will provide attendees with practical information that can be applied immediately in their clinical practice. Discussions will include the latest updates in recognizing symptoms and using current data to establish diagnoses and formulate appropriate treatment plans for the management of gastrointestinal diseases.
2. Learning Objectives

Evaluate and implement updated management guidelines for MASH, incorporating weight loss strategies and GLP-1 receptor agonists.

Apply advanced diagnostic and therapeutic approaches for autoimmune liver diseases, including AIH, PSC, and PBC.

Assess the clinical management of cirrhosis complications, including ascites, spontaneous bacterial peritonitis (SBP), and portal vein thrombosis.

Integrate addiction medicine principles into hepatology practice for the optimal care of patients with alcohol-associated liver disease.

Analyze current strategies for hepatocellular carcinoma (HCC) surveillance and evaluate complex liver lesions utilizing LI-RADS classifications.

3. Target Audience

Best for gastroenterologists and hepatologists who want updates on MASH, ALD, cirrhosis management, and hepatocellular carcinoma surveillance.

4. Topics

01 Advances in MASH

02 Updates in ALD (10 Management 10 New Frontiers)

03 Addiction Medicine for the Gastroenterologist Hepatologist

04 Q&A with Panel Session 1

05 Liver Disease in Pregnancy

06 PSC PBC Cases

07 AIH Updates in 2025

08 Panel Q&A Session 2

09 Case Presentation – Hereditary Hemochromatosis

10 Case Presentation – Drug Induced Liver Injury

11 Case Presentation – MASLD

12 Panel Q&A – Coffee, Weight Loss and GLP-1s to Treat MASLD

13 Debate Primary Prophylaxis of Esophageal Varices

14 Management of Ascites; SBP Prophylaxis

15 Patient Cases (PVT – INCPH)

16 Panel Q&A – Ascites, Portal Vein Thrombosis, and Anticoagulation in Cirrhosis

17 Patient Cases (HBV – Treatment, HBVr New Practice Guidelines)

18 Referral for LTE

19 Malnutrition and Frailty in the Cirrhosis Patient

20 Updates in HCC Surveillance

21 Liver Lesion Cases (Benign, LR-3 LR-4, HCC)